Durable remission with salvage decitabine and donor lymphocyte infusion (DLI) for relapsed early T-cell precursor ALL

Bone Marrow Transplant. 2017 Nov;52(11):1583-1584. doi: 10.1038/bmt.2017.191. Epub 2017 Sep 11.

Authors

F El Chaer^{1

2}, N Holtzman^{1

2}, E Binder^{1

2}, N C Porter³, Z N Singh⁴, M Koka⁴, A P Rapoport^{1

2}, A Emadi^{1

2}

Affiliations

¹ University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
² Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
³ Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, USA.
⁴ Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.

PMID: 28892087
DOI: 10.1038/bmt.2017.191

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Azacitidine / analogs & derivatives*
Azacitidine / therapeutic use
Decitabine
Humans
Lymphocyte Transfusion / methods*
Male
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Remission Induction / methods
Salvage Therapy / methods*
Treatment Outcome

Substances

Decitabine
Azacitidine